Non-Gene Editing CAR

About iCell Gene Therapeutics

iCell Gene Therapeutics is a pioneering clinical-stage biotech developing novel CAR-engineered cell therapies for autoimmune diseases and cancer. The company claims a first-in-world clinical application of CAR therapy for lupus, with data showing durable remission approaching six years, and is also advancing programs for T-cell malignancies and acute myeloid leukemia (AML). Its strategy leverages a proprietary technology platform, including compound CARs (cCARs) and non-gene editing approaches, supported by in-house viral vector and GMP manufacturing capabilities in China to enable cost-effective production.

Therapeutic Areas

Other T-cell Malignancies Drugs